Matthew Pauls's Trading History
| PTHSPelthos Therapeutics | Jul 07, 2026 | Director | Uninformative Sell | 20.56K | $135.02K | |
| SLNOSoleno Therapeutics | May 18, 2026 | ― | Uninformative Sell | ― | $0.00 | |
| SVRASavara | Dec 16, 2025 | CEO, Director | Uninformative Sell | 1.35M | $5.73M | |
| ZCORZyla Life Sciences | May 21, 2020 | ― | Uninformative Sell | ― | $0.00 | |
| SBBPStrongbridge Biopharma | Feb 22, 2019 | ― | Uninformative Buy | ― | $145.22K | |
| INSMInsmed | ― | CCO | ― | $0.00 | ||
| PVLAPalvella Therapeutics | ― | Director | ― | ― |
You May Also Like
Matthew Pauls insider profile FAQ
What is the percentage of profitable transactions made by Matthew Pauls?
The percentage of profitable transactions made by Matthew Pauls is 75%.
What is the average return per transaction made by Matthew Pauls?
The average return per transaction made by Matthew Pauls is 16.50%.
What stocks does Matthew Pauls hold?
Matthew Pauls holds: PTHS, SLNO, PVLA, SBBP, SVRA, ZCOR, INSM stocks.
What was Matthew Pauls’s latest transaction?
Matthew Pauls’s latest transaction was an Uninformative Sell of $20.56K.
What was Matthew Pauls's most profitable transaction?
Matthew Pauls’s most profitable transaction was an Informative Buy of SVRA stock on December 8, 2021. The return on the trade was 53.30%.
What is Matthew Pauls's role in Pelthos Therapeutics?
Matthew Pauls's role in Pelthos Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.